Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Neurology Drugs in Phase I Clinical Development in FRANCE

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Theranexus

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              FRANCE France

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO IMPACT

              Participation Not Confirmed

              Update your events

              Theranexus Announces The Clinical Results Of Its Phase Ib Study Demonstrating The Extended Pharmacological Profile Of Its Drugn Candidate Th...

              Contact the Supplier

              Lead Product(s): Donepezil,Mefloquine

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 15, 2020

              Details:

              THN201 significantly increased EEG power in the gamma band related to cognitive activity. Similar profile with respect to other pharmacological, pharmacokinetic and tolerance endpoints was observed.

              PharmaCompass__DigitalAd